printed one by

one, regulated by none

Problem statement

Additive manufacturing (3D printing) is increasingly used to produce patient-specific medical devices — surgical guides, cranial plates, spinal cages, dental prosthetics — and emerging bioprinting technologies aim to fabricate living tissue constructs. But the FDA's regulatory framework was designed for mass-manufactured devices produced under controlled factory conditions, not for one-off devices fabricated at the point of care in hospital 3D printing labs. It is unclear whether a hospital printing a patient-specific surgical guide is a "manufacturer" subject to FDA oversight, what quality management system requirements apply, and how postmarket surveillance works for one-of-a-kind devices. For bioprinted constructs incorporating living cells, no FDA-approved product exists and no regulatory pathway adequately addresses the unique risks of combining device and biologic properties.

Why this matters

Over 100 U.S. hospitals now operate 3D printing labs producing patient-specific surgical planning tools, guides, and implants. The global medical 3D printing market is projected to exceed $5 billion by 2028. Point-of-care manufacturing offers same-day surgical guides and anatomically matched implants — real clinical benefits — but uncontrolled quality means defective devices may reach patients without the safety checks that centralized manufacturing provides. Bioprinting, while still largely pre-clinical, has the potential to address organ transplant shortages, but regulatory uncertainty is cited as a primary barrier to clinical translation.

What’s been tried and why it hasn’t worked

The FDA issued guidance on "Technical Considerations for Additive Manufactured Medical Devices" in 2017, but it was written for factory-based additive manufacturing and does not specifically address point-of-care manufacturing. The FDA has suggested that point-of-care devices might be regulated as custom devices (exempt from premarket review under certain conditions) or as manufacturer-specific cleared devices, but neither pathway is clearly defined. ASTM published F3559 in April 2024 — the first standard for bioprinting terminology and considerations for bioinks — but it covers only extrusion bioprinting and focuses on terminology rather than safety validation. A 2025 industry survey found that manufacturers consider FDA additive manufacturing guidance ambiguous and requiring further clarity. Quality control for point-of-care 3D printing currently relies on hospital-specific institutional protocols that vary widely, with no standardized validation methodology.

What would unlock progress

A regulatory framework that distinguishes between factory-based and point-of-care additive manufacturing — with clear registration, quality management, and validation requirements for hospital-based 3D printing — would resolve the current jurisdictional ambiguity. For bioprinted products, a classification pathway that accounts for the device-biologic combination (currently falling between CDRH and CBER jurisdictions) would unblock clinical translation. Non-destructive testing methods capable of validating patient-specific geometries without destroying the actual device would solve the fundamental quality assurance challenge.

Entry points for student teams

A student team could survey 3D printing labs across multiple hospitals to document current quality management practices, identify common failure modes, and propose a minimum-viable quality standard for point-of-care manufacturing. Alternatively, a team could develop a non-destructive testing protocol for a specific class of 3D-printed device (e.g., surgical guides), comparing printing parameters, material properties, and dimensional accuracy across different printer platforms. A design-focused team could prototype a quality assurance workflow — from digital file to finished device — that a hospital 3D printing lab could adopt.